Status:
UNKNOWN
Molecular Targets for the Treatment of Histiocytosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
National Cancer Institute, France
Direction de l'Hospitalisation et de l'Organisation des Soins
Conditions:
Histiocytosis
Eligibility:
All Genders
Brief Summary
The primary objective: to develop technical and operating procedures for detection mutations of histiocytosis during clinical practice of no-specialized molecular platforms, for diagnosis and follow-u...
Detailed Description
The study is ancillary of the French "Gene Histio" cohort (patients already included) and "HISTIO target 2020" cohort (patients recruited since may 2020). The data base of the French registry of hist...
Eligibility Criteria
Inclusion
- Histologically proven histiocytosis;
- Informed consent form signed by patients (or parents/legal tutors of children) to participate"Gene Histio" or "HISTIO target 2020".
Exclusion
- \- Patient refusal.
Key Trial Info
Start Date :
November 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT04437381
Start Date
November 22 2021
End Date
May 1 2025
Last Update
September 6 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Biological research center, Ambroise Paré hospital, APHP
Boulogne-Billancourt, France, 92100
2
Department of internal Medicine, Pitié-Salpétrière hospital, APHP
Paris, France, 75013
3
Department of Pediatrics, Trousseau hospital, APHP
Paris, France